Overview
Plain-language guide
Designed and approved for specific uses that include Barth syndrome, Mitochondrial disease research.
It is intended to affect mitochondria—the parts of cells that manage energy. That mechanism does not automatically translate into better exercise or recovery.
Clinical mechanism
Binds mitochondrial cardiolipin and localizes to the inner mitochondrial membrane.
Applications
Human evidence
Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.
Tier 2Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Muscle & recovery profile
Each signal is scored independently from 0–5. There is no composite “best” score.
Evidence classes
What has been studied
- Mitochondrial disease studies include functional and exercise-related outcomes in defined populations.
What is not established
- Evidence from rare mitochondrial disease does not establish performance or recovery benefits in healthy people.
Studied populations
- People with Barth syndrome
- Other mitochondrial-disease research populations
Major limitations
- Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
- Findings from one population, formulation or indication should not be generalized to another.
Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.
Regulatory status
Approved. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Stealth BioTherapeutics · Accelerated approval. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
August 5, 2026 · Reviewed